Drug Trial Radar · NCT07552987
A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
38
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Kedrion S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of QIVIGY (Intravenous Human Normal Immune Globulin 10%) compared with placebo in adult participants with stiff person syndrome (SPS).
Conditions
- Stiff Person Syndrome
Interventions
Kedrion IVIg 10%Biological
Intravenous human normal immunoglobulin (IVIg) 10%
Human AlbuminBiological
Human albumin solution, diluted with saline 0.9% to a final concentration of 0.5% as an intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Timed 25-Foot Walk (T25-FW)Time frame: Baseline to Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.